IL238958B - Glutaminase inhibitors, preparations containing them and their uses - Google Patents

Glutaminase inhibitors, preparations containing them and their uses

Info

Publication number
IL238958B
IL238958B IL238958A IL23895815A IL238958B IL 238958 B IL238958 B IL 238958B IL 238958 A IL238958 A IL 238958A IL 23895815 A IL23895815 A IL 23895815A IL 238958 B IL238958 B IL 238958B
Authority
IL
Israel
Prior art keywords
compositions
same
glutaminase inhibitors
glutaminase
inhibitors
Prior art date
Application number
IL238958A
Other languages
English (en)
Hebrew (he)
Other versions
IL238958A0 (en
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL238958A0 publication Critical patent/IL238958A0/en
Publication of IL238958B publication Critical patent/IL238958B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL238958A 2012-11-22 2015-05-21 Glutaminase inhibitors, preparations containing them and their uses IL238958B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (2)

Publication Number Publication Date
IL238958A0 IL238958A0 (en) 2015-07-30
IL238958B true IL238958B (en) 2019-09-26

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238958A IL238958B (en) 2012-11-22 2015-05-21 Glutaminase inhibitors, preparations containing them and their uses

Country Status (36)

Country Link
US (2) US10087172B2 (https=)
EP (2) EP2922850B1 (https=)
JP (2) JP6333277B2 (https=)
KR (1) KR20150085079A (https=)
CN (2) CN104936954B (https=)
AR (1) AR093598A1 (https=)
AU (2) AU2013347771B2 (https=)
BR (1) BR112015011830A2 (https=)
CA (1) CA2893510C (https=)
CL (1) CL2015001392A1 (https=)
CR (1) CR20150316A (https=)
CY (1) CY1120581T1 (https=)
DK (1) DK2922850T3 (https=)
EA (2) EA030646B1 (https=)
EC (1) ECSP15026557A (https=)
ES (1) ES2690390T3 (https=)
HR (1) HRP20181628T1 (https=)
HU (1) HUE040111T2 (https=)
IL (1) IL238958B (https=)
LT (1) LT2922850T (https=)
MX (1) MX367389B (https=)
MY (1) MY177344A (https=)
NZ (1) NZ708382A (https=)
PE (1) PE20151072A1 (https=)
PH (2) PH12015501150B1 (https=)
PL (1) PL2922850T3 (https=)
PT (1) PT2922850T (https=)
RS (1) RS57859B1 (https=)
SA (1) SA515360469B1 (https=)
SG (2) SG10201609940RA (https=)
SI (1) SI2922850T1 (https=)
SM (1) SMT201800504T1 (https=)
TR (1) TR201812360T4 (https=)
TW (2) TW201906825A (https=)
UA (1) UA117360C2 (https=)
WO (3) WO2014079011A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
BR112015010955A2 (pt) 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
BR112015012536A2 (pt) * 2012-12-03 2017-07-11 Calithera Biosciences Inc tratamento de câncer com inibidores heterocíclicos da glutaminase
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
US10000479B2 (en) * 2014-03-21 2018-06-19 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EP3556757A1 (en) * 2014-04-30 2019-10-23 Pfizer Inc Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
WO2016004404A2 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
BR112017021312A2 (pt) 2015-04-06 2018-06-26 Calithera Biosciences Inc tratamento de câncer de pulmão com inibidores de glutaminase
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004359A1 (en) * 2015-06-30 2017-01-05 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
SG11201804664XA (en) 2015-12-22 2018-07-30 Univ Texas Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
KR20190040302A (ko) 2016-08-25 2019-04-17 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와의 병용 요법
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
EP3876928B1 (en) 2018-11-08 2024-10-23 Merck Sharp & Dohme LLC Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
DE69425882T2 (de) 1993-03-29 2001-01-11 Basf Ag 1-amino-3-phenoxy-propan-derivate als modulatoren bei multi-drug resistenz
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
CA2332325A1 (en) * 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
AU2008326497B2 (en) 2007-11-19 2014-02-13 Genentech, Inc. Compositions and methods for inhibiting tumor progression
WO2009111067A2 (en) 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
US20120142028A1 (en) 2009-04-17 2012-06-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
ES2638522T3 (es) 2010-06-23 2017-10-23 University Of Louisville Research Foundation, Inc. Procedimientos para detectar cáncer
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
EP2844270A4 (en) 2012-03-15 2016-01-27 Univ New York State Res Found COMBINATION THERAPIES WITH INHIBITORS OF THE EXTRACELLULAR DOMAIN OF E-CADHERINE
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US20160008380A1 (en) 2013-03-06 2016-01-14 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
US10000479B2 (en) 2014-03-21 2018-06-19 Agios Pharmaceuticals, Inc. Compounds and their methods of use

Also Published As

Publication number Publication date
JP6333277B2 (ja) 2018-05-30
WO2014079011A1 (en) 2014-05-30
UA117360C2 (uk) 2018-07-25
WO2014079150A1 (en) 2014-05-30
MY177344A (en) 2020-09-13
SMT201800504T1 (it) 2018-11-09
PL2922850T3 (pl) 2018-12-31
ECSP15026557A (es) 2016-01-29
US20150291576A1 (en) 2015-10-15
US20190084976A1 (en) 2019-03-21
NZ708382A (en) 2020-04-24
SA515360469B1 (ar) 2017-07-11
TW201906825A (zh) 2019-02-16
JP2018150316A (ja) 2018-09-27
CA2893510C (en) 2021-01-19
US10689375B2 (en) 2020-06-23
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
TW201427963A (zh) 2014-07-16
TR201812360T4 (tr) 2018-09-21
SG10201609940RA (en) 2016-12-29
CN104936954A (zh) 2015-09-23
MX367389B (es) 2019-08-19
CL2015001392A1 (es) 2016-04-22
AU2013347771B2 (en) 2018-02-01
PE20151072A1 (es) 2015-08-26
EA030646B1 (ru) 2018-09-28
LT2922850T (lt) 2018-09-10
PT2922850T (pt) 2018-10-15
HRP20181628T1 (hr) 2018-12-14
CN104936954B (zh) 2018-08-14
AU2018202954A1 (en) 2018-05-17
PH12015501150A1 (en) 2015-08-17
RS57859B1 (sr) 2018-12-31
SI2922850T1 (sl) 2018-10-30
EA201590987A1 (ru) 2015-12-30
HUE040111T2 (hu) 2019-02-28
EP2922850B1 (en) 2018-07-18
PH12015501150B1 (en) 2018-05-04
US10087172B2 (en) 2018-10-02
AR093598A1 (es) 2015-06-10
EA201890754A1 (ru) 2018-08-31
EP3456719A1 (en) 2019-03-20
CN108727307A (zh) 2018-11-02
CR20150316A (es) 2015-08-28
TWI629268B (zh) 2018-07-11
JP2016500082A (ja) 2016-01-07
IL238958A0 (en) 2015-07-30
EP2922850A1 (en) 2015-09-30
ES2690390T3 (es) 2018-11-20
SG11201504049VA (en) 2015-07-30
EP2922850A4 (en) 2016-05-18
CY1120581T1 (el) 2019-07-10
CA2893510A1 (en) 2014-05-30
PH12017502141A1 (en) 2019-02-27
HK1214593A1 (en) 2016-07-29
AU2013347771A1 (en) 2015-06-11
BR112015011830A2 (pt) 2017-07-11
WO2014079136A1 (en) 2014-05-30
DK2922850T3 (en) 2018-10-08

Similar Documents

Publication Publication Date Title
IL238958B (en) Glutaminase inhibitors, preparations containing them and their uses
IL238959A (en) Glutamase suppressors, preparations containing them and their uses
IL252063A0 (en) dna-pk suppressors, preparations containing them and their uses
IL233503A0 (en) Isocitrate dehydrogenase inhibitors, preparations containing them and their uses
IL246061B (en) Prodrugs of pyridone amide, preparations containing them and their uses
IL235155B (en) Arginase inhibitor compounds, compositions comprising same and uses thereof
IL241330B (en) pk - dna suppressor compounds, preparations containing them and their uses
IL269964A (en) Pyridone amide compounds, compositions containing them and uses thereof
HUE044300T2 (hu) 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk
IL234014A (en) Cycloalkane derivatives, preparations containing them and their uses
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
EP2802330A4 (en) IRAQ INHIBITORS AND USES THEREOF
EP2872518A4 (en) IRAQ INHIBITOR AND USES THEREOF
IL238876A0 (en) Indoleamine 2,3-dioxygenase inhibitors, preparations containing them and their uses
IL235585A0 (en) Substances that bind to ha, preparations containing them and their uses
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL241355A0 (en) Pyrazole-amide compounds, preparations containing them and their uses
ZA201402903B (en) Amide compounds, compositions and applications thereof
IL236712A0 (en) Di-teri-heteroaryl derivatives, preparations containing them and their uses
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
IL237542B (en) Amphiphilic compounds, their preparations and uses
IL237540B (en) Amphiphilic compounds, their preparations and uses
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
IL267888B (en) Amphiphilic compounds, their preparations and uses

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees